Tissue Regenix acquires CellRight Technologies

Date: September 14, 2017

CellRight Technologies, a US-based producer of regenerative osteoinductive bone scaffolds, has been acquired by Tissue Regenix Group plc (TRG). The deal was finalised on 9 August 2017.

CellRight, brings a complementary regenerative technology to TRG which can be applied to allograft bone, following a process that removes DNA from tissue, so that malleable applications such as DBM putty, strips, blocks and fibres can be produced. These are targeted for use in spine, orthopaedics and dental surgeries.

The deal allows TRG to leverage the capabilities of CellRight Technologies’ tissue bank in San Antonio, Texas and is strategic given the planned launch of TRG’s OrthoPure™ decellularised human tendon for anterior cruciate ligament repair in the US in early 2018. The San Antonio facility will also provide a purpose-built US base for the manufacture of products utilising the dCELL® process.

The acquisition provides the benefit of a combined, broad portfolio of innovative soft tissue and bone products and is expected to lead to the commercialisation of a pipeline of regenerative treatments.

Back to News Overview